Details

---

• Active Ingredients: Each tablet contains 48.6 mg sacubitril and 51.4 mg valsartan (as sacubitril/valsartan sodium salt complex).

• Marketing Authorisation (MAL): MAL15125061ARZ

• Manufacturer: Novartis Farma S.p.A., Italy

Content

• Active Ingredients per Tablet:

  • Sacubitril: 48.6 mg

  • Valsartan: 51.4 mg

• Formulation: Film-coated tablet for oral administration.

• Pack Size: 60 tablets per pack.

Indications

Entresto is indicated for the treatment of symptomatic chronic heart failure with reduced ejection fraction in adults. It is used in combination with other heart failure therapies, replacing an ACE inhibitor or angiotensin II receptor blocker (ARB). The benefits are most evident in patients with left ventricular ejection fraction below normal.

Instructions

Dosage:

• Starting Dose: 100 mg twice daily.

• Titration: After 2–4 weeks, the dose may be increased to 200 mg twice daily, depending on patient tolerance.

• Special Populations:

  • For patients not currently taking an ACE inhibitor or ARB, a starting dose of 50 mg twice daily is recommended, with gradual titration.

  • In patients with moderate renal impairment (eGFR 30–60 mL/min/1.73 m²) or moderate hepatic impairment (Child-Pugh B), initiate with 50 mg twice daily.